TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. Patients must give written informed consent before any assessment is performed.~2. Male, non-fertile female or female of childbearing potential using a medically approved birth control method based on local regulations.~3. Drug naïve type 2 diabetes patients, defined as who neither take consecutive anti-hyperglycemic drug treatment more than 3 months anytime, nor any anti-hyperglycemic drug treatment in 4 weeks prior to visit 1.~4. Age in the range of 18-75 years inclusive.~5. HbA1c in the range of \> 6.5 to ≤9.0% at Visit 1.~Exclusion criteria~1. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\>5 mIU/mL).~2. With known hypersensitivity to Nateglinide, Acarbose or any of the excipients.~3. A history of,~   1. type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes, e.g., Cushing's syndrome and acromegaly.~  2. acute metabolic diabetic complications such as ketoacidosis or hyperosmolar state (coma) within the past 6 months.~  3. Torsades de pointes, sustained and clinically relevant ventricular tachycardia or ventricular fibrillation.~  4. percutaneous coronary intervention within the past 3 months.~  5. any of the following within the past 6 months: myocardial infarction (MI), coronary artery bypass surgery, unstable angina, or stroke.~4. Evidence of significant diabetic complications, e.g., symptomatic autonomic neuropathy or gastroparesis.~5. Acute infections which may affect blood glucose control within 4 weeks prior to visit 1.~6. Congestive heart failure requiring pharmacologic treatment. mg/dL (123μmol/L)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Nateglinide (Type: EXPERIMENTAL): Nateglinide tablets, oral administration, three times daily, 120 mg orally 10 minutes immediately before 3 meals three times daily.
- Acarbose (Type: ACTIVE_COMPARATOR): Acarbose tablets, oral administration, three times daily, dosage of 50 mg orally chewing with the first bite of a meal three times daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Expert System to Reduce Depression in Primary Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At risk for or experiencing depression (i.e., Beck Depression Inventory-II (BDI) score of 10 or higher; current major depression, minor depression, or dysthymia; or past major depression, minor depression, or dysthymia)~Exclusion Criteria:~* Younger than age 18~* Involved in counseling or planning counseling in the next 30 days~* Taking antidepressant medication or planning to take antidepressants in the next 30 days (exclusion criterion for Untreated Sample only)~* Suicidal ideation~* Severe depression (BDI \> 28) and deemed inappropriate for study by site clinician~* BDI \<10 and in the Maintenance stage for using effective methods to prevent or reduce depression~* History of bipolar disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Computer-tailored intervention (Type: EXPERIMENTAL): Stage-based manual and three computer-tailored reports
- Usual care (Type: NO_INTERVENTION): Usual primary care treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients who completed the D1002001 study~・Patients who completed the D1002001 study and who are considered by the investigator to be eligible and without safety concerns.~Patients who did not participate in the D1002001 study~* Patients who were fully informed of and understand the objectives, procedures, and possible benefits and risks of the study and who provided written voluntary consent to participate in the study.~* Outpatients aged 18 through 74 years at the time of consent~* Patients meets DSM-IV-TR criteria for bipolar I disorder, most recent episode manic, hypomanic, or mixed with or without rapid cycling disease course (≥ 4 episodes of mood disturbance, but \< 8 episodes in the previous 12 months prior to screening).~Exclusion Criteria:~* Patients with imminent risk of suicide or injury to self, others, or property.~* Patients who are otherwise considered ineligible for the study by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- SM-13496 20-120mg (Type: EXPERIMENTAL): once daily orally SM-13496 20-120 mg flexibly dosed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Coaching for Caregivers of Children With Spinal Cord Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* female primary caregiver of youth between 6-13 years of age with traumatic spinal cord injury~* female primary caregivers have legal guardianship of their child with spinal cord injury~* speak, read and comprehend English~* be available for face-to-face coaching~* have a cell phone with text messaging capabilities, and willing to utilize cell or land line for coaching and data collection~* able to verbalize changes in their own participation or their child's participation during initial screen~* written consent~Exclusion Criteria:~* severe mental health condition of female caregiver, as documented in child's medical record or reported to research staff by child's treating MD or medical team member~* abuses illicit or prescribed substances or alcohol at time of initial screen as documented in child's medical record or reported to research staff by child's treating MD or medical team member

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- coaching in context (Type: OTHER): 10, 1 hour sessions of face to face strength based coaching sessions provided face to face or over the phone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antioxidation Medication for Noise-induced Hearing Loss

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* workers in steel industry~* known exposure to noise at work~Exclusion Criteria:~* ever diagnosed as having diabetes mellitus~* fasting glucose of 120 or greater

- Gender: MALE
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Acetin (Type: EXPERIMENTAL): None
- Glucose (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant must have skin lesions that are diagnostic of Hidradenitis Suppurativa (HS) for at least 1 year (365 days) prior to the Baseline visit~* Participant must have at least 3 distinct anatomical regions involved with inflammatory (also termed 'active') HS lesions; plus~  * either one axilla or one inguinal region (limited to the inguino-crural fold and adjacent areas) that requires excisional surgery, and~ * with at least one of the other affected HS regions (e.g., contralateral inguinal region, buttocks, inframammary region) rated as Hurley Stage II or III~* Participant must have a total abscess and inflammatory nodule (AN) count of greater than or equal to 3 at the Baseline visit within the HS non-surgical sites~* The HS surgical site must contain at least one active HS lesion~* The HS surgical site must require excisional surgery and is large enough to require healing by secondary intention as assessed by the designated surgeon~Exclusion Criteria:~* Participant has a draining fistula count of greater than 20 at the Baseline visit~* Participant requires surgery at any anatomical site other than an unilateral axilla or inguinal region site~* Participant requires surgical management prior to Week 13~* Participant requires, based on the designated surgeon's assessment, excisional surgery with primary closure as the method of closure being most beneficial for the participant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Period A: Day 1- 4 subcutaneous (SC) injections; Week 2- 2 SC injections; Weeks 4-12- 1 SC injection each week~Period B: Weeks 13-14- 1 SC injection each week~Period C: Weeks 15-23- 1 SC injection each week
- Adalimumab (Type: ACTIVE_COMPARATOR): Period A: Day 1- 4 subcutaneous (SC) 40 mg injections; Week 2- 2 SC 40 mg injections; Weeks 4-12- 1 SC 40 mg injection each week~Period B: Weeks 13-14- 1 SC 40 mg injection each week~Period C: Weeks 15-23- 1 SC 40 mg injection each week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infected adults,~* age ≥ 18 years,~* with a once-a-day ritonavir-boosted darunavir 800mg/j containing regimen plus 2 NRTI (≥ 6 months),~* virologically controlled (VL ≤ 50 cp/ml,~* ≥ 1 year,~* at least 2 VL spaced at least 3 months apart in the last 12 months) CD4 count ≥ 300/mm3 ≥ 6 months,~* virus sensible to darunavir and the used NRTI (pretreatment resistance genotypic test available) and~* with no history of virological failure (VL \> 200 cp/mL after ≥ 6 months under PI and/or used NRTI),~* no current opportunistic infection,~* renal clearance ≥ 60 mL/min if tenofovir is used,~* transaminases (SGOT, SGPT) plasma levels \< 2N,~* hemoglobin \> 11 g/dL,~* platelets count \> 150 000/mm3,~* negative pregnancy test in women with childbearing potential,~* informed written consent signed by both the investigator and the subject,~* national insurance scheme (article L1121-11 of the French Public Health code),~* no participation to any other clinical trial~Exclusion Criteria:~* HIV-2 infection,~* current antiretroviral therapy different from a once-a-day ritonavir-boosted darunavir 800mg/j containing regimen plus 2 NRTI,~* virus genotypically resistant to darunavir and the used NRTIs,~* history of virological failure (VL \> 200 cp/mL after ≥ 6 months under PI and/or used NRTI),~* irregular follow-up and/or history of lack of adherence to ART ≤ 12 months,~* current pregnancy,~* current opportunistic infection,~* associated treatment containing one or more drugs interacting with hepatic cytochromes,~* any addictive behaviors (alcohol consumption, drugs ...) likely to jeopardize the safety of the treatment and / or patient compliance and adherence to the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Darunavir 400mg/d (Type: EXPERIMENTAL): Tri-therapy containing Darunavir at dose of 400 mg/d.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/= 18 years of age~* Locally advanced or metastatic (stage IIIB/IV) non-small cell lung cancer (NSCLC)~* ECOG performance status 0-3~* Treatment phase: histologically confirmed EGFR exon 19 deletion or exon 21 mutation in the diagnostic phase of the study~* Adequate haematological, liver and renal function~* Female patients must be postmenopausal, surgically sterile, or agree to use a barrier method of contraception~* Male patients must be surgically sterile or agree to use a barrier method of contraception~Exclusion Criteria:~* Previous treatment for NSCLC with chemotherapy or therapy against EGFR, either with antibody or small molecule (tyrosine kinase inhibitor)~* Symptomatic cerebral metastases~* Pregnant or lactating women~* Any other concomitant anti-cancer therapy (until disease progression and discontinuation of Tarceva therapy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: S0701, Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori (H. Pylori)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* positive Urea Breath Test documenting H. pylori infection~* age 21 - 65 years~* no known allergies to study drugs~* only member of household participating in study~* no known medical conditions (other than H. pylori) that would preclude or require antibiotic therapy~* patients must be willing to discontinue alcohol use for 15 days (maximum duration of treatment plus one day)~* patients must be willing to discontinue use of antacids for duration of study treatment~* patients must not have used proton pump inhibitors (PPI) within 30 days of registration. Patients also must be willing to stop using non-study provided PPIs until the completion of the 6 week follow-up contact.~* patients must not have been treated with antibiotics for H. pylori in the past and must not have taken any other antibiotics within 30 days of registration.~* patients must be willing to return for 2 follow-up visits: 6 weeks after randomization following completion of treatment \& 1 year after randomization~* patients must be willing to allow submission of blood for assays of serum markers of bacterial virulence and host genetic susceptibility and environmental factors and provide consent for use of specimens.~Exclusion Criteria:~* current use of anti-retroviral therapy for HIV or AIDS~* diagnosed congestive hear failure~* renal failure requiring dialysis~* diagnosed hepatic failure resulting in hyperbilirubinemia~* any current or prior malignancy except: adequately treated basal or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or Stage II cancer from which the patient has been disease free for 5 years~* pregnancy or nursing mothers

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): Standard 14 day, 3-drug regimen
- Arm 2 (Type: EXPERIMENTAL): Concomitant Therapy - 5 day, 4-drug regimen
- Arm 3 (Type: EXPERIMENTAL): Sequential Therapy - 10 day, 4-drug regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* male or female subjects age 18 to 80 years, inclusive, with any International Prognostic Index score; treated with 6 or more cycles of first-line CHOP chemotherapy and achieved a PR, CRu, or CR~* de novo diffuse large B-cell NHL according to the REAL classification; Ann Arbor stage III, stage IV, or bulky stage II disease (any mass ≥10 cm in diameter)~* less than an average of 25% of the intratrabecular marrow space involved by NHL in bilateral bone marrow biopsy specimens or \<10% involvement with NHL from unilateral bone marrow biopsy; tumor tissue expressing the CD20 antigen~* ≥60% performance status on the Karnofsky Performance Scale and an anticipated survival of at least 3 months~* absolute neutrophil count (ANC) ≥1500 cells/mm3 and platelet count ≥100,000/mm3~* adequate renal function (serum creatinine \<1.5 × upper limit of normal \[ULN\]) and hepatic function (total bilirubin ≤2.0 × ULN and aspartate aminotransferase \<5 × ULN)~Exclusion Criteria:~* prior radiation, prior biological therapy, or prior chemotherapy other than first-line CHOP~* active bilateral obstructive hydronephrosis~* New York Heart Association class III or IV heart disease or other serious illness~* prior malignancy other than lymphoma (except for adequately treated skin cancer, in situ cervical cancer, or other cancer for which they had been disease-free for \>5 years)~* human immunodeficiency virus infection~* HAMA positive~* brain or leptomeningeal metastases at any time since diagnosis~* active infection requiring intravenous anti-infectives~* pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): tositumomab and iodine I-131 tositumomab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DS-5565 Phase III Study for Post-herpetic Neuralgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* PHN defined as pain present for more than 3 months after herpes zoster skin rash at screening~* At screening, a pain scale of ≥ 40 mm~Exclusion Criteria:~* Previous use of neurolytic block

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (14-weeks)
- DS-5565 15 mg Group (Type: EXPERIMENTAL): DS-5565 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
- DS-5565 20 mg Group (Type: EXPERIMENTAL): DS-5565 20 mg, oral administration, Treatment period; 1-week titration and 13-weeks fixed dose
- DS-5565 30 mg Group (Type: EXPERIMENTAL): DS-5565 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Repeated Mesenchymal Stem Cell Injections in ALS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females ages 18 to 70 years old, at the Screening Visit.~2. Sporadic or familial ALS diagnosed patients fulfilling the El Escorial clinical criteria for definite.~3. Capable of providing informed consent and willing and able to follow study procedures, including willingness to undergo multiple/repeated lumbar punctures.~4. ALSFRS-R ≥15 at the Screening Visit.~Exclusion Criteria:~1. Patients with severe cognitive decline or inability to understand and sign the informed consent.~2. Participation in another clinical trial within 1 year prior to start of the study~3. Patients with active infections.~4. Positive test for Hepatitis B, Hepatitis C, and/or HIV per laboratory evaluations at the screening visit.~5. Any history of solid malignancy including any malignancy affecting the central nervous system within 5 years of the Screening Visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Repeated MSCs treatment in ALS patients (Type: EXPERIMENTAL): Four intrathecal (IT) administrations of autologous MSC cells administered every 3 months in ALS patients. the IT treatment will be administered through a regular lumbar puncture at a dose of 1x10\^6 MSCs per kg body weight in 3 ml saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete